Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JC.2002-020068PMID 12213867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.

  2001cited by this paper
• Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

  2001influential reference
• Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

  2000influential reference
• Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

  2000cited by this paper
• Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.

  1999cited by this paper
• The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• The natural history of diabetes‐related complications: the UKPDS experience

  1999cited by this paper
• United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus

  1983cited by this paper

• Nutrition-related health outcomes of sweet potato (Ipomoea batatas) consumption: A systematic review

  2022cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Medications that cause weight gain and alternatives in Canada: a narrative review

  2018cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• The role of hormonal treatment in type 2 diabetes mellitus

  2015cites this paper
• Allongement de l'Intervalle QT acquis chez les Diabétiques au Service de Médecine Interne du CHU Tlemcen

  2015cites this paper
• Diabetes: A New Horizon and Approach to Management

  2015cites this paper
• Insulin therapy in type 2 diabetes : Initiation, impact on liver fat, role of combination therapy with glitazones or glindes

  2014cites this paper
• Effects of nateglinide and acarbose on glycemic excursions in standardized carbohydrate and mixed-meal tests in drug-naïve type 2 diabetic patients.

  2013cites this paper
• The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus

  2013cites this paper
• Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients.

  2013cites this paper
• Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.

  2012cites this paper
• Phytochemical constituents and pharmacological activities of Ipomoea batatas l. (Lam) – A review

  2012cites this paper
• Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.

  2012cites this paper
• Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence

  2012cites this paper
• Oral Agents for Type-2 Diabetes

  2011cites this paper
• Quo vadis nateglinide? Ten-year perspective

  2011cites this paper
• Evidence-based Synthesis Program

  2011cites this paper
• Effect of Meglitinides on Postprandial Ghrelin Secretion Pattern in Type 2 Diabetes Mellitus

  2010cites this paper
• Hypoglycemia, intensive glycemic control and diabetes care in care home residents with Type 2 diabetes

  2010cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2010cites this paper
• Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes

  2009cites this paper
• Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

  2009cites this paper
• Hypoglycaemia with Oral Antidiabetic Drugs

  2009cites this paper
• Diabetes: glycaemic control in type 2.

  2008cites this paper
• Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

  2008cites this paper
• Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia *

  2008cites this paper
• Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naïve elderly patients with type 2 diabetes

  2008cites this paper
• Meglitinide analogues for type 2 diabetes mellitus.

  2007cites this paper
• Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes.

  2007cites this paper
• A review of nateglinide in the management of patients with type 2 diabetes

  2007cites this paper
• Improvement of insulin sensitivity and β‐cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double‐blind and double‐dummy multicentre clinical trial

  2007cites this paper
• Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus

  2007cites this paper
• Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes

  2005cites this paper
• Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes

  2005cites this paper
• Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm.

  2005cites this paper
• PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.

  2005cites this paper
• Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.

  2005cites this paper
• An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives.

  2005cites this paper
• Postmarketing surveillance study of nateglinide in Japan

  2005cites this paper
• Oral Agents for Type 2 Diabetes: An Update

  2005cites this paper
• Nateglinide – current and future role in the treatment of patients with type 2 diabetes mellitus

  2005cites this paper
• Hypoglycaemia in Elderly Patients with Diabetes Mellitus

  2004cites this paper
• Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.

  2004cites this paper
• GLP-1: Target for a New Class of Antidiabetic Agents?

  2004cites this paper
• Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet.

  2004cites this paper
• Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

  2004cites this paper
• Clinical characteristics of nateglinide response as assessed by insulinogenic indices: Preliminary study to determine an optimal indication for nateglinide

  2003cites this paper
• Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.

  2003cites this paper
• Hypoglycemia in diabetes.

  2003cites this paper
• Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.

  2003cites this paper
• Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

  2003cites this paper
• Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.

  2002cites this paper
• : Targets

  year unknowncites this paper
• : Targets

  year unknowncites this paper